These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 34469062)

  • 1. Machine learning gene expression predicting model for ustekinumab response in patients with Crohn's disease.
    He M; Li C; Tang W; Kang Y; Zuo Y; Wang Y
    Immun Inflamm Dis; 2021 Dec; 9(4):1529-1540. PubMed ID: 34469062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intestinal mRNA expression profiles associated with mucosal healing in ustekinumab-treated Crohn's disease patients: bioinformatics analysis and prospective cohort validation.
    Li Q; Huang Z; Yang H; Tang J; Zuo T; Yang Q; Huang Z; Guo Q; Li M; Gao X; Chao K
    J Transl Med; 2024 Jun; 22(1):595. PubMed ID: 38926732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying hub genes in response to ustekinumab and the impact of ustekinumab treatment on fibrosis in Crohn's disease.
    Xu Y; Wang S; Ye Z; Zhang H
    Front Immunol; 2024; 15():1401733. PubMed ID: 38840917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease: a Chinese real-world study.
    Yao JY; Zhang M; Wang W; Peng X; Zhao JZ; Liu T; Li ZW; Sun HT; Hu P; Zhi M
    BMC Gastroenterol; 2021 Oct; 21(1):380. PubMed ID: 34663208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility of a Clinical Decision Support Tool for Ustekinumab to Predict Clinical Remission and Relapse in Patients With Crohn's Disease: A Multicenter Observational Study.
    Park J; Chun J; Yoon H; Cheon JH
    Inflamm Bowel Dis; 2023 Apr; 29(4):548-554. PubMed ID: 35670522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive models assessing the response to ustekinumab highlight the value of therapeutic drug monitoring in Crohn's disease.
    Liefferinckx C; Hubert A; Thomas D; Bottieau J; Minsart C; Cremer A; Amininejad L; Vallée F; Toubeau JF; Franchimont D
    Dig Liver Dis; 2023 Mar; 55(3):366-372. PubMed ID: 35977875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence, Dose Titration, and Health Care Resource Utilization Among Crohn's Disease Patients Treated With Ustekinumab: A Real-World Analysis in the United States.
    Obando C; Ding Z; Muser E; Vaidya N; Qiang W; Sun X; Wang H; Mallampati R; Xie L
    Adv Ther; 2020 May; 37(5):2127-2143. PubMed ID: 32193810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE).
    Eberl A; Hallinen T; Af Björkesten CG; Heikkinen M; Hirsi E; Kellokumpu M; Koskinen I; Moilanen V; Nielsen C; Nuutinen H; Suhonen UM; Utriainen K; Vihriälä I; Soini E; Wennerström C; Nissinen R; Borsi A; Koivunen M; Tillonen J; Sipponen T
    Scand J Gastroenterol; 2019 Jun; 54(6):718-725. PubMed ID: 31184512
    [No Abstract]   [Full Text] [Related]  

  • 9. Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn's disease: A systematic review and meta-analysis.
    Yoshihara T; Shinzaki S; Amano T; Iijima H; Takehara T; Inoue N; Uchino M; Esaki M; Kobayashi T; Saruta M; Sugimoto K; Nakamura S; Hata K; Hirai F; Hiraoka S; Fujii T; Matsuura M; Matsuoka K; Watanabe K; Nakase H; Watanabe M
    J Gastroenterol Hepatol; 2021 Jul; 36(7):1744-1753. PubMed ID: 33450096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Paediatric Patients With Medically Refractory Crohn's Disease Using Ustekinumab: A Multi-Centred Cohort Study.
    Chavannes M; Martinez-Vinson C; Hart L; Kaniki N; Chao CY; Lawrence S; Jacobson K; Hugot JP; Viala J; Deslandres C; Jantchou P; Seidman EG
    J Crohns Colitis; 2019 Apr; 13(5):578-584. PubMed ID: 30541021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn's Disease.
    Painchart C; Brabant S; Duveau N; Nachury M; Desreumaux P; Branche J; Gérard R; Prevost CLD; Wils P; Lambin T; Boualit M; Labalette M; Pariente B
    Dig Dis Sci; 2020 May; 65(5):1445-1452. PubMed ID: 31599389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ustekinumab Improves Active Crohn's Disease by Suppressing the T Helper 17 Pathway.
    Ihara Y; Torisu T; Miyawaki K; Umeno J; Kawasaki K; Hirano A; Fujioka S; Fuyuno Y; Matsuno Y; Sugio T; Sasaki K; Moriyama T; Akashi K; Kitazono T
    Digestion; 2021; 102(6):946-955. PubMed ID: 34350861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ustekinumab therapy for Crohn's disease during pregnancy: a case report and review of the literature.
    Cortes X; Borrás-Blasco J; Antequera B; Fernandez-Martinez S; Casterá E; Martin S; Molés JR
    J Clin Pharm Ther; 2017 Apr; 42(2):234-236. PubMed ID: 28004853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ustekinumab serum concentrations are associated with clinical outcomes in Crohn's disease - a regional multi-center pilot study.
    Thomann AK; Schulte LA; Globig AM; Hoffmann P; Klag T; Itzel T; Teufel A; Schreiner R; Scheffe N; Ebert MP; Wehkamp J; Gauss A; Hasselblatt P; Klaus J; Reindl W
    Z Gastroenterol; 2020 May; 58(5):439-444. PubMed ID: 32045954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn's disease.
    Hirayama H; Morita Y; Imai T; Takahashi K; Yoshida A; Bamba S; Inatomi O; Andoh A
    BMC Gastroenterol; 2022 Apr; 22(1):195. PubMed ID: 35448957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated multiple microarray studies by robust rank aggregation to identify immune-associated biomarkers in Crohn's disease based on three machine learning methods.
    Chen ZA; Ma HH; Wang Y; Tian H; Mi JW; Yao DM; Yang CJ
    Sci Rep; 2023 Feb; 13(1):2694. PubMed ID: 36792688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study.
    Liefferinckx C; Verstockt B; Gils A; Noman M; Van Kemseke C; Macken E; De Vos M; Van Moerkercke W; Rahier JF; Bossuyt P; Dutré J; Humblet E; Staessen D; Peeters H; Van Hootegem P; Louis E; Franchimont D; Baert F; Vermeire S;
    J Crohns Colitis; 2019 Oct; 13(11):1401-1409. PubMed ID: 30989232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidence.
    Engel T; Yung DE; Ma C; Pariente B; WIls P; Eliakim R; Ungar B; Ben-Horin S; Kopylov U
    Dig Liver Dis; 2019 Sep; 51(9):1232-1240. PubMed ID: 31202609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting diagnostic biomarkers associated with immune infiltration in Crohn's disease based on machine learning and bioinformatics.
    Bao W; Wang L; Liu X; Li M
    Eur J Med Res; 2023 Jul; 28(1):255. PubMed ID: 37496049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Ustekinumab on Crohn's Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD).
    Macaluso FS; Fries W; Viola A; Costantino G; Muscianisi M; Cappello M; Guida L; Giuffrida E; Magnano A; Pluchino D; Ferracane C; Magrì G; Di Mitri R; Mocciaro F; Privitera AC; Camilleri S; Garufi S; Renna S; Casà A; Scrivo B; Ventimiglia M; Orlando A
    Expert Opin Biol Ther; 2020 Nov; 20(11):1381-1384. PubMed ID: 32981373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.